Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2022 | Key data in sarcoma presented at ASCO 2022

Brian Van Tine • 4 Jun 2022
ASCO 2022
Gastrointestinal Cancer Sarcoma Unesbulin

Brian Van Tine, MD, PhD, Washington University School of Medicine in St.Louis, St Louis, MO, talks on promising new data presented at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting, including data on NY-ESO-1 for myxoid/round cell liposarcoma and the BMI1 inhibitor unesbulin for the treatment of Ewing sarcoma. This interview took place at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting in Chicago, IL.

More from Brian Van Tine

0:54
What does the future hold for CAR T-cells in sarcoma management?
Brian Van Tine • 4 Jun 2023
0:33
Predicative biomarkers of response to immunotherapy in STS
Brian Van Tine • 4 Jun 2023
0:50
SPEARHEAD-1: afamitresgene autoleucel in advanced synovial sarcoma
Brian Van Tine • 4 Jun 2023
0:57
Cabozantinib with checkpoint inhibition in soft tissue sarcoma
Brian Van Tine • 4 Jun 2023

Related Videos

1:53
Important pathophysiological determinants of elevated cirDNA post-surgery
Alain Thierry • 9 Apr 2024
0:47
Emerging molecular drivers and biomarker targets in gastroesophageal cancers
Tatsuhiro Shibata • 9 Apr 2024
0:52
DRP-104 with durvalumab in fibrolamellar hepatocellular carcinoma
Marina Baretti • 9 Apr 2024
1:06
The emerging role of cancer vaccines in treating liver cancer
Marina Baretti • 9 Apr 2024
The content of VJOncology is intended for healthcare professionals